To demonstrate that our technology can enhance the efficacy ofimmune checkpoint blockade therapy, we evaluated its efficacy in combinationwith the immune checkpoint inhibitor anti-PD-1, which is the mostcommonly used form of immunotherapy.41 Weselected CT26 colon carcinoma as our disease model due to its documentedlow-to-moderate response rate to checkpoint inhibitors.42 In this model, we dosed p(Man-TLR7-PDS) intratumorallyand anti-PD-1 systemically. This evidence concerns the gene TLR7 and colon carcinoma.